Seattle Genetics is a top firm that is renowned for its expertise in the development of targeted cancer cures. The company has significantly helped in improving cancer treatment by founding the antibody-drug conjugates (ADC) technology. Unlike chemotherapy, ADCs are very safe, and they do not have harmful side effects. Seattle Genetics was established by Clay Siegall and a few biotechnology research professionals in 1998. He is the corporation’s CEO and chairman. Clay has strived to ensure that the firm grows from being a research hub to a drug manufacturer that sells its products across the globe.
Under Clay’s management, Seattle Genetics has developed a flagship drug that is known as Adcetris. The cure focuses on Hodgkin lymphoma, which is a dangerous cancer of the lymph that spreads to other parts of the body. The drug has been approved by the FDA and has also been commercialized in 64 different countries. Clay has led public offering and private financing transactions that have enabled the Seattle Genetics to raise over $675 million. In May 2016, he revealed that the company was planning to develop 12 more cures.
Dr. Siegall pursued a Ph.D. in Genetics at the George Washington University before establishing Seattle Genetics. He served research enterprises such as Bristol-Myers Squibb Pharmaceutical Research Institute and the government-owned National Cancer Institute. His career experience makes him very resourceful in the biotechnology research sector, and therefore, he has been appointed by different corporations as a board member. He sits on the board of directors of Mirna Therapeutics, which is a Texas-based biotechnology research enterprise. The company depends on Clay’s expertise to develop iRNA-targeting therapeutics. He also serves the boards of the Ultragenyx and Alder BioPharmaceuticals.
For the past three decades, Clay Siegall has done a lot of research work that has made him be appreciated in the pharmaceuticals sector. He has founded several new cures and has patented 15 of them. The biotechnologist was on the front line in the discovery of ADCs. He hopes that his company’s inventions will save the lives of cancer patients and has partnered with multinational pharmaceutical companies to ensure that they reach all parts of the globe.